February 2025 - Page 14 of 15

Release – ODP Business Solutions Joins New, Multi-Year, Multi-Award $500M Annual Furniture Partnership with Region 4 Education Service Center

Posted on February 4, 2025February 4, 2025 by dburczyk@noblecapitalmarkets.com

New Contract unlocks potential growth opportunities and provides discounts on quality furniture and furnishing solutions from hundreds of manufacturers through purchasing cooperative

BOCA RATON, Fla.–(BUSINESS WIRE)–Feb. 4, 2025– ODP Business Solutions, a leading supplier of workplace solutions and services and a division of The ODP Corporation (NASDAQ: ODP), announced participation in a new award for a multi-year furniture contract with Region 4 Education Service Center (ESC) that brings the potential of up to $500M in total annual revenue. The contract enables the ODP Business Solutions Workspace Interiors team to offer a compliant cooperative purchasing solution through OMNIA Partners, providing furniture, installation, and related services to K-12 schools, higher education institutions, and cities and counties across the United States.

Region 4 ESC, member of and lead agency for OMNIA Partners, serves as a premier purchasing organization for state and local government, K-12 education, colleges and universities. Region 4 ESC assists school districts in improving student performance, provides efficient fiscal management and builds collaborative relationships and partnerships.

“At ODP Business Solutions we understand that the right learning and working environment can boost productivity and inspire students, educators and administrators,” said David Centrella, executive vice president of The ODP Corporation and president of ODP Business Solutions. “Our Workspace Interiors team is dedicated to delivering innovative and flexible solutions that meet the evolving needs of modern spaces. We look forward to providing these cost-effective products and services through our continued partnership with Region 4 ESC.”

The new contract grants OMNIA Partners members access to a comprehensive range of products designed for diverse environments, including breakrooms, classrooms, administrative offices, libraries, cafeterias, lobbies and more. This competitively solicited, publicly awarded Region 4 cooperative contract ensures compliance with procurement standards, allowing public sector agencies to streamline their purchasing process and save money with discounted offerings.

“Part of our mission is to equip school districts with the services and products they need to operate more efficiently and economically,” said Jorgannie Carter, chief of finance and business services at Region 4 Education Service Center. “Our contract with ODP Business Solutions will allow us to optimize our resources and continue providing schools and professionals with high-quality, affordable products.”

Region 4 serves a seven-county area composed of 48 public school districts and 43 public charter schools, representing more than 1.2 million students and more than 111,000 professional educators.

In recent years, ODP Business Solutions has been awarded five contracts, showing the company’s commitment to supporting public sector organizations with innovative, tailored and cost-effective solutions. To learn more about ODP Business Solutions, visit www.odpbusiness.com.

About ODP Business Solutions:

ODP Business Solutions is a trusted partner with more than 30 years of experience working with businesses to adapt to the ever-changing world of work. From technology transformation, sustainability, innovative workspace design, cleaning and breakroom, and everything in between, ODP Business Solutions has the integrated products and services businesses need. Powered by a collaborative team of experienced business consultants, world-class logistics, and trusted brand names, ODP Business Solutions advances how the working world gets work done. For more information on ODP Business Solutions, visit www.odpbusiness.com.

ODP Business Solutions is a division of The ODP Corporation (NASDAQ: ODP). ODP and ODP Business Solutions are trademarks of ODP Business Solutions, LLC. Any other product or company names mentioned herein are the trademarks of their respective owners.

FORWARD LOOKING STATEMENTS – THE ODP CORPORATION

This communication may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements or disclosures may discuss goals, intentions and expectations as to future trends, plans, events, results of operations, cash flow or financial condition, or state other information relating to, among other things, The ODP Corporation (“the Company”), based on current beliefs and assumptions made by, and information currently available to, management. Forward-looking statements generally will be accompanied by words such as “anticipate,” “believe,” “plan,” “could,” “estimate,” “expect,” “forecast,” “guidance,” “expectations”, “outlook,” “intend,” “may,” “possible,” “potential,” “predict,” “project,” “propose” “aim” or other similar words, phrases or expressions, or other variations of such words. These forward-looking statements are subject to various risks and uncertainties, many of which are outside of the Company’s control. There can be no assurances that the Company will realize these expectations or that these beliefs will prove correct, and therefore investors and stakeholders should not place undue reliance on such statements. Investors and shareholders should carefully consider the foregoing factors and the other risks and uncertainties described in the Company’s Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K filed with the U.S. Securities and Exchange Commission. The Company does not assume any obligation to update or revise any forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250204940684/en/

Press Contact:
Katee Schalau
6600 North Military Trail
Boca Raton, FL 33496
mediarelations@odpbusiness.com

Source: ODP Business Solutions

Release – LODE: Comstock Fuels Approved for $152 Million Allocation for Oklahoma Qualified Private Activity Bonds

Posted on February 4, 2025February 4, 2025 by dburczyk@noblecapitalmarkets.com

Research News and Market Data on LODE

OKLAHOMA CITY, OKLAHOMA – FEBRUARY 4, 2025 – Comstock Inc. (NYSE: LODE) today announced that its subsidiary, Comstock Fuels Corporation (“Comstock Fuels”), was approved by the Oklahoma State Treasurer’s Office to issue up to $152 million in qualified private activity bonds.

This allocation of up to $152 million in Qualified Private Activity Bonds that can be issued by Comstock Fuels represents a major achievement in Comstock Fuels’ plans for financing and building its first 400,000 barrel per year commercial demonstration facility in a soon-to-be-selected site in Oklahoma.

This overall approval by the Oklahoma State Treasurer’s Office comes under the Oklahoma Private Activity Bond Allocation Act and would consist of allocations from the Oklahoma Economic Development Pool, the Oklahoma Exempt Facilities Pool, and the Oklahoma Carryforward Pool. The Oklahoma Development Finance Authority (“ODFA”) sponsored this bond allocation to support the State’s essential infrastructure projects with Comstock’s first Oklahoma commercial biorefining facility.

“This allocation is a foundational component of our overall capital and financing plans for Comstock Fuels, including funding each of our planned Bioleum™ Refineries in the U.S. with dedicated project financing,” said Chad Michael Black, Director of Business Development at Comstock Fuels. “Oklahoma has taken a leadership role in accelerating advanced domestic energy solutions and the support from the State Treasurer’s Office and the ODFA underscores our strong alignment with Oklahoma for developing, deploying and operating diverse, scalable and essential energy infrastructure for our communities.”

“We are rapidly achieving the critical prerequisites for securing the project financing needed to build our first commercial demonstration facility, with over $150 million of that objective supported by Oklahoma’s tax-efficient, municipal revenue bond allocation, $3 million in direct Oklahoma-based grants, and a growing group of strategic investors,” stated Corrado De Gasperis, Executive Chairman of Comstock and Comstock Fuels. “We’re also close to selecting an investment banking partner to facilitate the bond placement and underwriting. We’re thrilled to receive such strong support from Oklahoma as we integrate feedstock, site infrastructure, and offtake into a whole new standard for domestic energy production.”

Private activity bonds under the Internal Revenue Code (the “Code”) are described generally as any bond: (1) of which more than 10% of the proceeds is to be used in a trade or business of any person or persons other than a governmental unit or which is to be directly or indirectly repaid, or secured by revenues from a private trade or business; and (2) in which an amount exceeding the lesser of 5% or $5 million of the proceeds is to be used for loans to any person or persons other than a governmental unit.

The Federal Tax Reform Act of 1986 established limits on the volume of private activity bonds that may be issued in a state during any calendar year. To ensure compliance with federal law, the Oklahoma legislature passed the Oklahoma Private Activity Bond Allocation Act.

Most private activity bonds must be sold on a taxable basis. However, the Code grants exceptions when certain bonds can be sold on a tax-exempt basis (“Qualified Private Activity Bonds”). Such bonds, with certain exceptions, are subject to the federal alternative minimum tax. The Code also imposes a limitation on the amount of Qualified Private Activity Bonds which may be issued by a state in any calendar year.

About Comstock Fuels Corporation

Comstock Fuels Corporation (“Comstock Fuels”) delivers advanced lignocellulosic biomass refining solutions that set industry benchmarks for production of cellulosic ethanol, gasoline, renewable diesel, sustainable aviation fuel (“SAF”), and other renewable Bioleum™ fuels, with extremely low carbon intensity scores of 15 and market-leading yields of up to 140 gallons per dry metric ton of feedstock (on a gasoline gallon equivalent basis, or “GGE”), depending on feedstock, site conditions, and other process parameters. Comstock Fuels additionally holds the exclusive rights to intellectual properties developed by Hexas Biomass Inc. (“Hexas”) for production of purpose grown energy crops in liquid fuels applications with proven yields exceeding 25 to 30 dry metric tons per acre per year. The combination of Comstock Fuels’ high yield Bioleum refining platform and Hexas’ high yield energy crops allows for the production of enough feedstock to produce upwards of 100 barrels of fuel per acre per year, effectively transforming marginal agricultural lands with regenerative practices into perpetual “drop-in sedimentary oilfields” with the potential to dramatically boost regional energy security and rural economies.

Comstock Fuels plans to contribute to domestic energy dominance by directly building, owning, and operating a network of Bioleum Refineries in the U.S. to produce about 200 million barrels of renewable fuel per year by 2035, starting with its planned first 400,000 barrel per year commercial demonstration facility in Oklahoma. Comstock Fuels also licenses its advanced feedstock and refining solutions to third parties for additional production in the U.S. and global markets, including several recently announced and other pending projects. To learn more, please visit www.comstockfuels.com.

About Comstock Inc.

Comstock Inc. (NYSE: LODE) innovates and commercializes technologies that are deployable across entire industries to contribute to energy abundance by efficiently extracting and converting under-utilized natural resources, such as waste and other forms of woody biomass into renewable fuels, and end-of-life electronics into recovered electrification metals. Comstock’s innovations group is also developing and using artificial intelligence technologies for advanced materials development and mineral discovery for sustainable mining. To learn more, please visit www.comstock.inc.

Comstock Social Media Policy

Comstock Inc. has used, and intends to continue using, its investor relations link and main website at www.comstock.inc in addition to its Twitter, LinkedIn and YouTube accounts, as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

Contacts

For investor inquiries:
RB Milestone Group LLC
Tel (203) 487-2759
ir@comstockinc.com

For media inquiries or questions:
Colby Korsun
Comstock Fuels Corporation
fuels@comstockinc.com

Forward-Looking Statements

This press release and any related calls or discussions may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, are forward-looking statements. The words “believe,” “expect,” “anticipate,” “estimate,” “project,” “plan,” “should,” “intend,” “may,” “will,” “would,” “potential” and similar expressions identify forward-looking statements but are not the exclusive means of doing so. Forward-looking statements include statements about matters such as: future market conditions; future explorations or acquisitions; future changes in our research, development and exploration activities; future financial, natural, and social gains; future prices and sales of, and demand for, our products and services; land entitlements and uses; permits; production capacity and operations; operating and overhead costs; future capital expenditures and their impact on us; operational and management changes (including changes in the Board of Directors); changes in business strategies, planning and tactics; future employment and contributions of personnel, including consultants; future land and asset sales; investments, acquisitions, joint ventures, strategic alliances, business combinations, operational, tax, financial and restructuring initiatives, including the nature, timing and accounting for restructuring charges, derivative assets and liabilities and the impact thereof; contingencies; litigation, administrative or arbitration proceedings; environmental compliance and changes in the regulatory environment; offerings, limitations on sales or offering of equity or debt securities, including asset sales and associated costs; business opportunities, growth rates, future working capital, needs, revenues, variable costs, throughput rates, operating expenses, debt levels, cash flows, margins, taxes and earnings. These statements are based on assumptions and assessments made by our management in light of their experience and their perception of historical and current trends, current conditions, possible future developments and other factors they believe to be appropriate. Forward-looking statements are not guarantees, representations or warranties and are subject to risks and uncertainties, many of which are unforeseeable and beyond our control and could cause actual results, developments, and business decisions to differ materially from those contemplated by such forward-looking statements. Some of those risks and uncertainties include the risk factors set forth in our filings with the SEC and the following: adverse effects of climate changes or natural disasters; adverse effects of global or regional pandemic disease spread or other crises; global economic and capital market uncertainties; the speculative nature of gold or mineral exploration, and lithium, nickel and cobalt recycling, including risks of diminishing quantities or grades of qualified resources; operational or technical difficulties in connection with exploration, metal recycling, processing or mining activities; costs, hazards and uncertainties associated with precious and other metal based activities, including environmentally friendly and economically enhancing clean mining and processing technologies, precious metal exploration, resource development, economic feasibility assessment and cash generating mineral production; costs, hazards and uncertainties associated with metal recycling, processing or mining activities; contests over our title to properties; potential dilution to our stockholders from our stock issuances, recapitalization and balance sheet restructuring activities; potential inability to comply with applicable government regulations or law; adoption of or changes in legislation or regulations adversely affecting our businesses; permitting constraints or delays; challenges to, or potential inability to, achieve the benefits of business opportunities that may be presented to, or pursued by, us, including those involving battery technology and efficacy, quantum computing and generative artificial intelligence supported advanced materials development, development of cellulosic technology in bio-fuels and related material production; commercialization of cellulosic technology in bio-fuels and generative artificial intelligence development services; ability to successfully identify, finance, complete and integrate acquisitions, joint ventures, strategic alliances, business combinations, asset sales, and investments that we may be party to in the future; changes in the United States or other monetary or fiscal policies or regulations; interruptions in our production capabilities due to capital constraints; equipment failures; fluctuation of prices for gold or certain other commodities (such as silver, zinc, lithium, nickel, cobalt, cyanide, water, diesel, gasoline and alternative fuels and electricity); changes in generally accepted accounting principles; adverse effects of war, mass shooting, terrorism and geopolitical events; potential inability to implement our business strategies; potential inability to grow revenues; potential inability to attract and retain key personnel; interruptions in delivery of critical supplies, equipment and raw materials due to credit or other limitations imposed by vendors; assertion of claims, lawsuits and proceedings against us; potential inability to satisfy debt and lease obligations; potential inability to maintain an effective system of internal controls over financial reporting; potential inability or failure to timely file periodic reports with the Securities and Exchange Commission; potential inability to list our securities on any securities exchange or market or maintain the listing of our securities; and work stoppages or other labor difficulties. Occurrence of such events or circumstances could have a material adverse effect on our business, financial condition, results of operations or cash flows, or the market price of our securities. All subsequent written and oral forward-looking statements by or attributable to us or persons acting on our behalf are expressly qualified in their entirety by these factors. Except as may be required by securities or other law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Neither this press release nor any related calls or discussions constitutes an offer to sell, the solicitation of an offer to buy or a recommendation with respect to any securities of the Company, the fund, or any other issuer.

Job Openings Decline Sharply in December, Falling Below Forecast

Posted on February 4, 2025February 4, 2025 by slightbourne@noblecapitalmarkets.com

Key Points:
– Job openings dropped to 7.6 million in December, the lowest level since September and below the estimated 8 million.
– The decline in openings came despite a net gain of 256,000 nonfarm payroll jobs for the month.
– The Federal Reserve monitors job openings as a key indicator of labor market conditions.

The U.S. labor market saw a significant drop in available positions in December, with job openings falling to 7.6 million, according to the Bureau of Labor Statistics’ latest Job Openings and Labor Turnover Survey (JOLTS). This figure came in below the Dow Jones estimate of 8 million and marked the lowest level since September.

The decline in openings signals a potential softening in labor demand, even as the broader economy continues to add jobs. Nonfarm payrolls increased by 256,000 during the month, but the number of available positions fell by 556,000. As a share of the labor force, openings declined to 4.5%, marking a 0.4 percentage point drop from November.

Several industries saw notable declines in job openings, with professional and business services losing 225,000 positions. Private education and health services recorded a drop of 194,000, while the financial activities sector saw a decrease of 166,000. These losses indicate that some industries may be reassessing hiring plans in response to economic conditions and policy uncertainty.

Despite the drop in job openings, other labor market indicators remained stable. Layoffs for December totaled 1.77 million, down slightly by 29,000. Hiring edged up to 5.46 million, and voluntary quits—a measure of worker confidence—saw a small increase to nearly 3.2 million. Total separations, which include layoffs, quits, and other exits, remained largely unchanged at 5.27 million.

Following the report’s release, major stock market indexes posted gains, while Treasury yields saw mixed movement. Investors appeared to view the data as a sign that the labor market remains resilient, even as job openings decline. A more balanced labor market could provide support for Federal Reserve policymakers considering the timing of future interest rate changes.

The JOLTS report arrives just days ahead of the Bureau of Labor Statistics’ nonfarm payrolls report for January, which is expected to show an addition of 169,000 jobs, with the unemployment rate holding at 4.1%. Federal Reserve officials have been closely watching labor market trends as they assess monetary policy.

Last week, the central bank opted to keep its benchmark interest rate steady at 4.25% to 4.50%. While investors have been hoping for rate cuts, Fed officials have signaled caution, noting that they need more evidence of sustained economic conditions before making policy adjustments. Markets currently anticipate the first rate cut no sooner than June.

Overall, the decline in job openings could be an early sign of a cooling labor market, but steady hiring and stable unemployment suggest the economy is still holding up. The coming months will be crucial in determining whether this trend continues and how it may influence the Fed’s next moves on interest

Release – MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer

Posted on February 4, 2025February 4, 2025 by aweinsoff@channelchek.com

Research News and Market Data on MAIA

February 04, 2025 8:51am EST Download as PDF

Median overall survival (OS) from THIO treatment extends to 16.9 months
Newest data strengthens regulatory strategy

CHICAGO–(BUSINESS WIRE)– MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced positive updated data from its THIO-101 pivotal Phase 2 clinical trial evaluating its lead clinical candidate, THIO, sequenced with Regeneron’s immune checkpoint inhibitor (CPI) cemiplimab (Libtayo^®) in patients with advanced non-small cell lung cancer (NSCLC) who failed two or more standard-of-care therapy regimens.

As of January 15, 2025, third line (3L) data showed median overall survival (OS) of 16.9 months for the 22 NSCLC patients who received at least one dose of THIO (the intent-to-treat population) in parts A and B of the trial. The analysis demonstrated a 95% confidence interval (CI) lower bound of 12.5 months and a 99% CI lower bound of 10.8 months. The treatment has been generally well-tolerated to date in this heavily pre-treated population¹. Studies of standard-of-care (SOC) chemotherapy treatments for NSCLC in a similar setting have shown OS of 5 to 6 months.²

“Treatment with THIO now shows a 99% probability that overall survival will extend past chemotherapy’s measure by a wide margin,” said Vlad Vitoc, M.D., CEO of MAIA. “THIO’s efficacy in advanced stages of NSCLC continues to exceed our expectations, especially in third-line treatment where the cancer is typically even more resistant to therapy. Our findings suggest great benefits to patients with unmet medical needs who see little hope for the future.

“With our latest overall survival results, our outlook for potential FDA commercial approval of THIO is stronger than ever,” Dr. Vitoc concluded.

Based on its regulatory strategy, MAIA believes there could be an opportunity for accelerated FDA approval of THIO depending on final results from the ongoing expansion of the THIO-101 trial.

About THIO

THIO (6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2’-deoxyguanosine (THIO) induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. THIO-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment with THIO followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. THIO is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.

About THIO-101, a Phase 2 Clinical Trial

THIO-101 is a multicenter, open-label, dose finding Phase 2 clinical trial. It is the first trial designed to evaluate THIO’s anti-tumor activity when followed by PD-(L)1 inhibition. The trial is testing the hypothesis that low doses of THIO administered prior to cemiplimab (Libtayo^®) will enhance and prolong immune response in patients with advanced NSCLC who previously did not respond or developed resistance and progressed after first-line treatment regimen containing another checkpoint inhibitor. The trial design has two primary objectives: (1) to evaluate the safety and tolerability of THIO administered as an anticancer compound and a priming immune activator (2) to assess the clinical efficacy of THIO using Overall Response Rate (ORR) as the primary clinical endpoint. Treatment with THIO followed by cemiplimab (Libtayo^®) has been generally well-tolerated to date in a heavily pre-treated population. For more information on this Phase II trial, please visit ClinicalTrials.gov using the identifier NCT05208944.

About MAIA Biotechnology, Inc.

MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.

Forward Looking Statements

MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, “MAIA,” “Company,” “we,” “our,” and “us” refers to MAIA Biotechnology, Inc. and its subsidiaries.

__________________________

¹ Details on safety can be found on the previously announced SITC 2024 presentation available on MAIA’s website.

² Girard N, et al. J Thorac Onc 2009;12:1544-1549.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250204174307/en/

Investor Relations Contact
+1 (872) 270-3518
ir@maiabiotech.com

Source: MAIA Biotechnology, Inc.

Released February 4, 2025

Release – Century Lithium Provides Update on Angel Island and Lithium Extraction Facility

Posted on February 4, 2025February 4, 2025 by aweinsoff@channelchek.com

Research News and Market Data on CYDVF

February 4, 2025 – Vancouver, Canada – Century Lithium Corp. (TSXV: LCE) (OTCQX: CYDVF) (Frankfurt: C1Z) (“Century Lithium” or “the Company”) is pleased to provide an update on its wholly owned Angel Island project near Silver Peak, Nevada, USA and associated Lithium Extraction Facility (“Pilot Plant”) in Amargosa Valley Nevada. The Company has completed the successful implementation of process improvements at its Pilot Plant. These changes were developed in collaboration with Amalgamated Research, LLC (“ARi”) of Twin Falls, Idaho, a research and development company specializing in industrial implementation of process technologies. Century Lithium is now shifting the focus at its Pilot Plant from research and development to demonstration.

“The initial results from ARi are very encouraging, indicating greater efficiency can be achieved that could result in positive reductions in the estimated capital and operating costs at Angel Island,” said Century Lithium President and CEO, Bill Willoughby. “Century Lithium remains committed to delivering value to our shareholders through Angel Island, one of the few advanced lithium projects in the United States. We are optimistic about the long-term fundamentals of the lithium market and the strategic importance of Angel Island to the future mineral supply in the United States.”

Project Update

The processing testing program (“Program”) implemented ARi’s proprietary adsorption-based technology for Direct Lithium Extraction (“DLE”) and was accomplished in conjunction with ARi’s Twin Falls testing facilities and Century Lithium’s Pilot Plant. The results of the Program are positive and further validate the efficiency of Century Lithium’s extraction technology. The Program augmented Century Lithium’s DLE system with the addition of ARi equipment and expertise. Early results indicate Century Lithium can eliminate the recycle loops within its DLE and lithium carbonate areas, while increasing eluate grades. The Company believes this will result in a substantial reduction in estimated capital and operating costs at Angel Island.

The decision to shift the focus at the Pilot Plant to demonstration mode is two-fold; it will allow the Company to focus on providing dedicated testing to prospective strategic partners or potential end-users and reduce the ongoing operating costs of the Pilot Plant. Current Pilot Plant operations will continue to convert a backlog of lithium solutions, which were made prior to the commissioning of the on-site lithium carbonate process at the Pilot Plant, into battery-grade lithium carbonate.

Moving Forward

The Company recently announced a non-binding Memorandum of Understanding (“MOU”) with Orica Specialty Mining Chemicals (see news release). The non-binding MOU outlines the intent of Century Lithium and Orica to formalize a multiyear offtake agreement for Orica to purchase sodium hydroxide from Angel Island. The favorable outlook for the sodium hydroxide by-product contributes significantly to Century Lithium’s low-cost lithium carbonate production model.

Ongoing engineering is focused on mining, and the leaching, filtration, DLE, and lithium carbonate processing areas. The Company continues to compile all data generated at the Pilot Plant. The data will be used in engineering models and to run analytical tests on full-scale construction designs focused on further reducing the estimated capital and operating costs for producing lithium carbonate at Angel Island.

Century Lithium remains focused on seeking strategic partnerships with potential end-users and market participants interested in securing a domestic supply of battery-grade lithium carbonate. The Company continues to move forward with permitting work to ensure that our future operations at Angel Island will align with both regulatory requirements and Century Lithium’s environmental and social stewardship goals.

Qualified Person

Todd Fayram, MMSA-QP and Senior Vice President, Metallurgy of Century Lithium is the qualified person as defined by National Instrument 43-101 and has approved the technical information in this release.

ABOUT Ari

Amalgamated Research LLC (ARi) is a supplier of chromatography, adsorption, and ion exchange technology and equipment specialized in commercializing innovative technology at large industrial scale. ARi has developed a cost-effective and streamlined solution for adsorption-based direct lithium extraction that maximizes plant profitability while minimizing upfront capital cost. ARi’s patented fluid distribution and mixing technology de-risks scale-up allowing separation processes to be reliably scaled from pilot plant data up to industrial vessels exceeding 20-ft in diameter, with no degradation in equipment performance. ARi provides a full spectrum of customer support services, from proof of concept through to industrial-scale installation. Comprehensive analytical services and a wide range of pilot equipment are available on-site to support process development and scale-up. Please visit arifractal.net for more information.

ABOUT CENTURY LITHIUM CORP.

Century Lithium Corp. is an advanced stage lithium company, focused on developing its wholly owned Angel Island project in Esmeralda County, Nevada, which hosts one of the largest sedimentary lithium deposits in the United States. The Company has utilized its patent-pending process for chloride leaching combined with direct lithium extraction to make high purity lithium carbonate product samples from Angel Island lithium-bearing claystone on-site at its Pilot Plant in Amargosa Valley, Nevada.

Angel Island is one of the few advanced lithium projects in development in the United States to provide an end-to-end process to produce battery quality lithium carbonate for the growing electric vehicle and battery storage market. Angel Island is currently in the permitting stage for a three-phase feasibility-level production plan expected to yield an average of 34,000 tonnes per year of lithium carbonate over a 40-year mine-life.

Century Lithium trades on both the TSX Venture Exchange under the symbol “LCE” and the OTCQX under the symbol “CYDVF”; and on the Frankfurt Stock Exchange under the symbol “C1Z”.

To learn more, please visit centurylithium.com

ON BEHALF OF CENTURY LITHIUM CORP.

WILLIAM WILLOUGHBY, PhD., PE
President & Chief Executive Officer

For further information, please contact:
Spiros Cacos | Vice President, Investor Relations
Direct: +1 604 764 1851
Toll Free: 1 800 567 8181
scacos@centurylithium.com
centurylithium.com

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THE CONTENT OF THIS NEWS RELEASE.

Cautionary Note Regarding Forward-Looking Statements

This release contains certain forward-looking statements within the meaning of applicable Canadian securities legislation. In certain cases, forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved” and similar expressions suggesting future outcomes or statements regarding an outlook.

Forward-looking statements relate to any matters that are not historical facts and statements of our beliefs, intentions and expectations about developments, results and events which will or may occur in the future, without limitation, statements with respect to the potential development and value of the Project and benefits associated therewith, statements with respect to the expected project economics for the Project, such as estimates of life of mine, lithium prices, production and recoveries, capital and operating costs, IRR, NPV and cash flows, any projections outlined in the Feasibility Study in respect of the Project, the permitting status of the Project and the Company’s future development plans.

These and other forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of the Company to control or predict, that may cause their actual results, performance or achievements to be materially different from those expressed or implied thereby, and are developed based on assumptions about such risks, uncertainties and other factors set out herein. These risks include those described under the heading “Risk Factors” in the Company’s most recent annual information form and its other public filings, copies of which can be under the Company’s profile at www.sedarplus.com. The Company expressly disclaims any obligation to update-forward-looking information except as required by applicable law. No forward-looking statement can be guaranteed and actual future results may vary materially. Accordingly, readers are advised not to place reliance on forward-looking statements or information. Furthermore, Mineral Resources that are not Mineral Reserves do not have demonstrated economic viability.

Release – Tonix Pharmaceuticals Promotes Siobhan Fogarty to Chief Technical Officer

Posted on February 4, 2025February 4, 2025 by aweinsoff@channelchek.com

Research News and Market Data on TNXP

February 04, 2025 7:00am EST Download as PDF

Ms. Fogarty has served at Tonix since 2016, most recently as Executive Vice President, Product Development

Tonix is Preparing for Potential Launch of TNX-102 SL for the management of fibromyalgia with U.S. FDA PDUFA goal date of August 15, 2025

CHATHAM, N.J., Feb. 04, 2025 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced the promotion of Siobhan Fogarty to Chief Technical Officer (CTO), effective immediately. Ms. Fogarty joined Tonix in 2016 and previously served as Executive Vice President of Product Development. Ms. Fogarty has over 25 years of experience in pharmaceutical and biotech product development, manufacturing and quality, for both small and large molecules, at notable pharmaceutical and biotech companies.

In December, Tonix announced that the U.S. Food and Drug Administration (FDA) assigned a Prescription Drug User Fee Act (PDUFA) goal date of August 15, 2025, for a decision on marketing authorization for TNX-102 SL (cyclobenzaprine HCl sublingual tablets) 5.6 mg for the management of fibromyalgia. TNX-102 SL is a non-opioid, centrally-acting analgesic. Fibromyalgia is a common chronic pain condition that affects mostly women.

“Siobhan is an invaluable member of our team and an outstanding leader who has contributed in many ways to our success since she joined in 2016, and we are excited that she is executing at a higher level in her new role as our first CTO,” said Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals. “Her energy, insights and organizational abilities will be welcome as we enter into a landmark time for the Company with the upcoming PDUFA goal date of August 15, 2025, for TNX-102 SL for the management of fibromyalgia. In addition to her stewardship of TNX-102 SL, Siobhan has played key roles advancing our pipeline of small molecule, biologics and live-virus vaccines.”

Ms. Fogarty started her career with Elan Corporation as a formulation scientist where she gained experience in several different areas of drug delivery, including solid, liquids, IV, and transdermal formulations. At Elan, she took products from concept to commercial manufacture in both Ireland and the U.S. Ms. Fogarty moved to Glaxo SmithKline, London, as a manufacturing strategist after the merger of Glaxo and SmithKline Beecham. Returning to product development, Ms. Fogarty established European product development sites for Fuisz Technologies and Biovail Corporation, leading multi-disciplinary teams for the development of products from early conceptual/preclinical development, through the various clinical phases and transferring to U.S./Canadian manufacturing sites during registration for commercialization. Subsequently, Ms. Fogarty started a consultancy firm, eMSc, that advised pharmaceutical and biotech companies in product development and implementation of a phased approach to quality. Ms. Fogarty obtained her masters in Pharmaceutical Sciences at Trinity College, Dublin, and is a European Union Qualified Person. Her primary degree is in Industrial Chemistry from the University of Limerick where she interned at Pfizer.

“I am grateful for the incredible eight years I have already enjoyed working at Tonix and look forward to the challenges and opportunities of my new role,” said Ms. Fogarty. “Tonix is entering a momentous time, and it is an honor to assume these new responsibilities as part of this extraordinary team.”

Tonix Pharmaceuticals Holding Corp.^*

Tonix is a fully integrated biopharmaceutical company focused on transforming therapies for pain management and vaccines for public health challenges. Tonix’s development portfolio is focused on central nervous system (CNS) disorders. Tonix’s priority is to advance TNX-102 SL, a product candidate for the management of fibromyalgia, for which an NDA was submitted based on two statistically significant Phase 3 studies for the management of fibromyalgia and for which a PDUFA (Prescription Drug User Fee act) goal date of August 15, 2025 has been assigned for a decision on marketing authorization. The FDA has also granted Fast Track designation to TNX-102 SL for the management of fibromyalgia. TNX-102 SL is also being developed to treat acute stress reaction and acute stress disorder under a Physician-Initiated IND at the University of North Carolina in the OASIS study funded by the U.S. Department of Defense (DoD). Tonix’s CNS portfolio includes TNX-1300 (cocaine esterase), a biologic in Phase 2 development designed to treat cocaine intoxication that has FDA Breakthrough Therapy designation, and its development is supported by a grant from the National Institute on Drug Abuse. Tonix’s immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is an Fc-modified humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the area of infectious disease, including a vaccine for mpox, TNX-801. Tonix recently announced a contract with the U.S. DoD’s Defense Threat Reduction Agency (DTRA) for up to $34 million over five years to develop TNX-4200, small molecule broad-spectrum antiviral agents targeting CD45 for the prevention or treatment of infections to improve the medical readiness of military personnel in biological threat environments. Tonix owns and operates a state-of-the art infectious disease research facility in Frederick, Md. Tonix Medicines, our commercial subsidiary, markets Zembrace^® SymTouch^® (sumatriptan injection) 3 mg and Tosymra^® (sumatriptan nasal spray) 10 mg for the treatment of acute migraine with or without aura in adults.

* Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.

Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. All other marks are property of their respective owners.

This press release and further information about Tonix can be found at www.tonixpharma.com.

Forward Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the failure to successfully market any of our products; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission (the “SEC”) on April 1, 2024, and periodic reports filed with the SEC on or after the date thereof. All of Tonix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

Investor Contact

Jessica Morris
Tonix Pharmaceuticals
investor.relations@tonixpharma.com
(862) 799-8599

Peter Vozzo
ICR Healthcare
peter.vozzo@icrhealthcare.com
(443) 213-0505

Media Contact

Ray Jordan
Putnam Insights
ray@putnaminsights.com
(949) 245-5432

Indication and Usage

Zembrace^® SymTouch^® (sumatriptan succinate) injection (Zembrace) and Tosymra^® (sumatriptan) nasal spray are prescription medicines used to treat acute migraine headaches with or without aura in adults who have been diagnosed with migraine.

Zembrace and Tosymra are not used to prevent migraines. It is not known if Zembrace or Tosymra are safe and effective in children under 18 years of age.

Important Safety Information

Zembrace and Tosymra can cause serious side effects, including heart attack and other heart problems, which may lead to death. Stop use and get emergency help if you have any signs of a heart attack:

discomfort in the center of your chest that lasts for more than a few minutes or goes away and comes back
severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw
pain or discomfort in your arms, back, neck, jaw or stomach
shortness of breath with or without chest discomfort
breaking out in a cold sweat
nausea or vomiting
feeling lightheaded

Zembrace and Tosymra are not for people with risk factors for heart disease (high blood pressure or cholesterol, smoking, overweight, diabetes, family history of heart disease) unless a heart exam shows no problem.

Do not use Zembrace or Tosymra if you have:

history of heart problems
narrowing of blood vessels to your legs, arms, stomach, or kidney (peripheral vascular disease)
uncontrolled high blood pressure
hemiplegic or basilar migraines. If you are not sure if you have these, ask your provider.
had a stroke, transient ischemic attacks (TIAs), or problems with blood circulation
severe liver problems
taken any of the following medicines in the last 24 hours: almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, ergotamines, or dihydroergotamine. Ask your provider for a list of these medicines if you are not sure.
are taking certain antidepressants, known as monoamine oxidase (MAO)-A inhibitors or it has been 2 weeks or less since you stopped taking a MAO-A inhibitor. Ask your provider for a list of these medicines if you are not sure.
an allergy to sumatriptan or any of the components of Zembrace or Tosymra

Tell your provider about all of your medical conditions and medicines you take, including vitamins and supplements.

Zembrace and Tosymra can cause dizziness, weakness, or drowsiness. If so, do not drive a car, use machinery, or do anything where you need to be alert.

Zembrace and Tosymra may cause serious side effects including:

changes in color or sensation in your fingers and toes
sudden or severe stomach pain, stomach pain after meals, weight loss, nausea or vomiting, constipation or diarrhea, bloody diarrhea, fever
cramping and pain in your legs or hips; feeling of heaviness or tightness in your leg muscles; burning or aching pain in your feet or toes while resting; numbness, tingling, or weakness in your legs; cold feeling or color changes in one or both legs or feet
increased blood pressure including a sudden severe increase even if you have no history of high blood pressure
medication overuse headaches from using migraine medicine for 10 or more days each month. If your headaches get worse, call your provider.
serotonin syndrome, a rare but serious problem that can happen in people using Zembrace or Tosymra, especially when used with anti-depressant medicines called SSRIs or SNRIs. Call your provider right away if you have: mental changes such as seeing things that are not there (hallucinations), agitation, or coma; fast heartbeat; changes in blood pressure; high body temperature; tight muscles; or trouble walking.
hives (itchy bumps); swelling of your tongue, mouth, or throat
seizures even in people who have never had seizures before

The most common side effects of Zembrace and Tosymra include: pain and redness at injection site (Zembrace only); tingling or numbness in your fingers or toes; dizziness; warm, hot, burning feeling to your face (flushing); discomfort or stiffness in your neck; feeling weak, drowsy, or tired; application site (nasal) reactions (Tosymra only) and throat irritation (Tosymra only).

Tell your provider if you have any side effect that bothers you or does not go away. These are not all the possible side effects of Zembrace and Tosymra. For more information, ask your provider.

This is the most important information to know about Zembrace and Tosymra but is not comprehensive. For more information, talk to your provider and read the Patient Information and Instructions for Use. You can also visit https://www.tonixpharma.com or call 1-888-869-7633.

You are encouraged to report adverse effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Source: Tonix Pharmaceuticals Holding Corp.

Released February 4, 2025

Release – SelectQuote to Release Fiscal Second Quarter 2025 Earnings on February 10

Posted on February 4, 2025February 4, 2025 by aweinsoff@channelchek.com

Research News and Market Data on SLQT

02/03/2025

OVERLAND PARK, Kan.–(BUSINESS WIRE)– SelectQuote, Inc. (NYSE: SLQT), a leading distributor of Medicare insurance policies and owner of a rapidly growing Healthcare Services platform, today announced it will release its second quarter 2025 financial results after market close on Monday, February 10, 2025. Chief Executive Officer, Tim Danker, and Chief Financial Officer, Ryan Clement, will host a conference call on the day of the release (February 10, 2025) at 5:00 pm ET to discuss the results.

To register for this conference call, please use this link: https://registrations.events/direct/Q4I731198247.

After registering, a confirmation will be sent via email, including dial in details and unique conference call codes for entry. Registration is open through the live call, but to ensure you are connected for the full call, we suggest registering a day in advance or at minimum 10 minutes before the start of the call. The event will also be webcasted live via our investor relations website https://ir.selectquote.com/investor-home/default.aspx or via this link.

About SelectQuote:

Founded in 1985, SelectQuote (NYSE: SLQT) provides solutions that help consumers protect their most valuable assets: their families, health, and property. The company pioneered the model of providing unbiased comparisons from multiple, highly-rated insurance companies allowing consumers to choose the policy and terms that best meet their unique needs. Two foundational pillars underpin SelectQuote’s success: a strong force of highly-trained and skilled agents who provide a consultative needs analysis for every consumer, and proprietary technology that sources and routes high-quality leads.

With an ecosystem offering high touchpoints for consumers across insurance, medicare, pharmacy, and value-based care, the company now has four core business lines: SelectQuote Senior, SelectQuote Healthcare Services, SelectQuote Life, and SelectQuote Auto and Home. SelectQuote Senior serves the needs of a demographic that sees around 10,000 people turn 65 each day with a range of Medicare Advantage and Medicare Supplement plans. SelectQuote Healthcare Services is comprised of the SelectRx Pharmacy, a Patient-Centered Pharmacy Home™ (PCPH) accredited pharmacy, and Healthcare Select which proactively connects consumers with a wide breadth of healthcare services supporting their needs.

Investor Relations:
Sloan Bohlen
877-678-4083
investorrelations@selectquote.com

Media:
Matt Gunter
913-286-4931
matt.gunter@selectquote.com

Source: SelectQuote, Inc.

Euroseas (ESEA) – Updating Estimates Due to Two New Time Charters

Posted on February 4, 2025February 4, 2025 by cpereira@noblefcm.com

Tuesday, February 04, 2025

Euroseas Ltd. was formed on May 5, 2005 under the laws of the Republic of the Marshall Islands to consolidate the ship owning interests of the Pittas family of Athens, Greece, which has been in the shipping business over the past 140 years. Euroseas trades on the NASDAQ Capital Market under the ticker ESEA. Euroseas operates in the container shipping market. Euroseas’ operations are managed by Eurobulk Ltd., an ISO 9001:2008 and ISO 14001:2004 certified affiliated ship management company, which is responsible for the day-to-day commercial and technical management and operations of the vessels. Euroseas employs its vessels on spot and period charters and through pool arrangements.

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Hans Baldau, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

New time charter contracts. Euroseas executed two new time charter contracts for M/V Synergy Antwerp and M/V Synergy Keelung. The charter contracts are at gross daily rates of $35,500 for a minimum period of 36 months and a maximum period of 39 months at the charterer’s option. Both contracts will take effect at the completion of the vessels’ respective current charters; M/V Synergy Antwerp’s new charter is expected to commence in May 2025, and M/V Synergy Keelung’s new charter is expected to commence in June 2025.

Favorable rates and improved coverage. The new time charters are expected to contribute roughly $57.0 million in EBITDA during the minimum contracted period. The new charters improve the company’s 2025 and 2026 charter coverage to 82% and 45%, respectively. Additionally, Euroseas announced that M/V Synergy Keelung will be retrofitted with energy-saving devices (ESDs) and the upgrade costs will be shared with the charterer.

Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.

Palantir Soars 25% to Record High as AI Drives Strong Earnings and Growth

Posted on February 4, 2025February 4, 2025 by slightbourne@noblecapitalmarkets.com

Key Points:
– Palantir stock surged 25% to a record high following better-than-expected fourth-quarter results and strong guidance.
– The company’s U.S. commercial revenue grew 64% year over year, while U.S. government revenues rose 45%.
– CEO Alex Karp emphasized Palantir’s pivotal role in AI and national security, predicting sustained momentum over the next three to five years.

Palantir Technologies saw its stock price soar by 25% on Tuesday, hitting a record high after delivering robust fourth-quarter earnings and an optimistic outlook fueled by artificial intelligence (AI) advancements. The Denver-based software company reported adjusted earnings of 14 cents per share on revenue of $828 million, surpassing analysts’ expectations of 11 cents per share and $776 million in revenue.

The company also provided strong guidance for the first quarter of 2025, forecasting revenue between $858 million and $862 million—well above the $799 million analysts had anticipated. For the full year, Palantir expects revenue between $3.74 billion and $3.76 billion, again exceeding estimates of $3.52 billion. This impressive performance has driven Palantir’s stock up 36% year-to-date, continuing its explosive 340% growth throughout 2024 as AI adoption accelerates.

CEO and co-founder Alex Karp attributed the company’s momentum to the increasing adoption of its AI-powered platforms across both commercial and government sectors. Palantir’s U.S. commercial revenue surged 64% year over year, while its U.S. government revenue climbed 45%. Karp described the company’s trajectory as “unlike anything that has come before,” reinforcing its dominance in AI and data analytics.

Palantir, long recognized for its work with U.S. defense and intelligence agencies, has also seen rising demand for its AI-driven commercial software solutions. The company expects U.S. commercial sales to grow by 54% in 2025, reflecting broader enthusiasm for AI-driven business intelligence and operational efficiency.

“We are at the very beginning of our trajectory and the AI revolution,” Karp said in his letter to shareholders. “We plan to be a cornerstone—if not the cornerstone—company driving this transformation in the U.S. over the next three to five years.”

Karp also emphasized Palantir’s commitment to national security, stating that the company is “very long America” and aims to enhance U.S. military capabilities to deter potential adversaries. His comments come amid rising competition in AI, particularly following China’s DeepSeek AI breakthroughs, which have raised concerns over technological supremacy and national security implications.

The strong earnings report prompted several Wall Street firms to raise their price targets for Palantir’s stock. Bank of America analyst Mariana Perez Mora called Palantir an AI “value adder” and increased her price target, while Morgan Stanley upgraded the stock from underweight to equal weight. Analyst Sanjit Singh admitted that concerns over slowing growth had been overstated, saying, “Given the strength of the outlook, we acknowledge that we were wrong about our core fundamental catalyst of slowing growth below the 30% level.”

With AI adoption showing no signs of slowing, Palantir’s strong financial results and forward-looking guidance have solidified its status as a key player in the evolving AI landscape. Investors remain highly optimistic about the company’s future, as it continues to expand its AI-powered solutions across both public and private sectors.

Triumph Group Sells for $3 Billion: Private Equity Giants Berkshire Partners and Warburg Pincus Make Strategic Aerospace Bet

Posted on February 4, 2025February 4, 2025 by slightbourne@noblecapitalmarkets.com

Key Points:
– Triumph Group to be acquired for $3 billion by Warburg Pincus and Berkshire Partners
– Deal offers 123% premium to shareholders
– Transaction expected to close in second half of 2025
– Company will become privately held, focusing on aerospace component innovation

Triumph Group, a leading aerospace components manufacturer, has agreed to be acquired by affiliates of Warburg Pincus and Berkshire Partners in an all-cash transaction valued at approximately $3 billion. The deal, which will take the company private, represents a substantial premium of 123% over Triumph’s unaffected stock price and signals significant confidence in the aerospace industry’s future.

Under the terms of the agreement, Triumph shareholders will receive $26.00 per share in cash, a premium that demonstrates the strong strategic value perceived by the private equity firms. The transaction is expected to close in the second half of 2025, subject to shareholder approval and regulatory clearances.

Dan Crowley, Triumph’s chairman, president, and CEO, highlighted the strategic importance of the deal, noting that it will provide the company with enhanced capabilities to meet evolving customer needs. The transaction comes after years of portfolio optimization and building a world-class team of aerospace engineering professionals.

Warburg Pincus and Berkshire Partners bring extensive experience in the aerospace and defense sectors. Dan Zamlong from Warburg Pincus emphasized the firms’ deep investment history in aerospace platforms, expressing excitement about partnering with Triumph’s global team to capture growing demand for high-quality aerospace components.

The acquisition reflects the ongoing consolidation and strategic repositioning within the aerospace industry. Triumph, founded in 1993 and headquartered in Radnor, Pennsylvania, designs, develops, manufactures, and repairs aerospace and defense systems and components for both original equipment manufacturers and military and commercial aircraft operators.

Blake Gottesman of Berkshire Partners highlighted Triumph’s critical role in the aerospace and defense industry, noting the firm’s history of partnering with market-leading aerospace companies. The transaction is not contingent on financing, underscoring the financial strength of the acquiring partners.

Warburg Pincus brings significant financial muscle to the deal, with over $86 billion in assets under management and a diverse portfolio of over 230 companies. Berkshire Partners, a 100% employee-owned investor, is currently investing from its Fund XI, which closed in 2024 with approximately $7.8 billion in commitments.

The transaction will result in Triumph becoming a privately held company, delisting from the New York Stock Exchange. The company plans to continue its scheduled financial reporting, with third-quarter fiscal 2025 earnings expected to be released by February 10, 2025.

Release – Bitcoin Depot Adds Additional $5 Million in Bitcoin to its Treasury Holdings

Posted on February 3, 2025February 3, 2025 by aweinsoff@channelchek.com

Research News and Market Data on BTM

February 03, 2025 11:32 AM EST

Download as PDF

ATLANTA, Feb. 03, 2025 (GLOBE NEWSWIRE) — Bitcoin Depot (NASDAQ: BTM) (“Bitcoin Depot” or the “Company”), a U.S.-based Bitcoin ATM operator and leading fintech company, today announced it has purchased an additional $5 million in Bitcoin as part of its treasury strategy, first announced in June of last year.

With yesterday’s purchase of 51 BTC, the Company now holds 71.5 Bitcoin in its treasury, substantially increasing its position in the leading cryptocurrency.

“Adopting Bitcoin as part of our treasury strategy underscores our long-standing belief in Bitcoin as a significant financial asset and a store of value,” said Brandon Mintz, CEO of Bitcoin Depot. “We have always believed in providing easy access to Bitcoin for everyone, and this move reaffirms our confidence in Bitcoin’s potential for growth. Given the recent accounting standards update, it also allows our shareholders to benefit from future BTC appreciation.”

About Bitcoin Depot
Bitcoin Depot Inc. (Nasdaq: BTM) was founded in 2016 with the mission to connect those who prefer to use cash to the broader, digital financial system. Bitcoin Depot provides its users with simple, efficient and intuitive means of converting cash into Bitcoin, which users can deploy in the payments, spending and investing space. Users can convert cash to bitcoin at Bitcoin Depot kiosks in 48 states and at thousands of name-brand retail locations in 29 states through its BDCheckout product. The Company has the largest market share in North America with approximately 8,400 kiosk locations as of December 31, 2024. Learn more at www.bitcoindepot.com.

Cautionary Statement Regarding Forward-Looking Statements
This press release and any oral statements made in connection herewith include “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act of 1934, as amended. Forward-looking statements are any statements other than statements of historical fact, and include, but are not limited to, statements regarding the expectations of plans, business strategies, objectives and growth and anticipated financial and operational performance, including our growth strategy and ability to increase deployment of our products and services, our ability to strengthen our financial profile, and worldwide growth in the adoption and use of cryptocurrencies. These forward-looking statements are based on management’s current beliefs, based on currently available information, as to the outcome and timing of future events. Forward-looking statements are often identified by words such as “anticipate,” “appears,” “approximately,” “believe,” “continue,” “could,” “designed,” “effect,” “estimate,” “evaluate,” “expect,” “forecast,” “goal,” “initiative,” “intend,” “may,” “objective,” “outlook,“ ”plan,“ ”potential,“ ”priorities,“ ”project,“ ”pursue,“ ”seek,“ ”should,“ ”target,“ ”when,“ ”will,“ ”would,” or the negative of any of those words or similar expressions that predict or indicate future events or trends or that are not statements of historical matters, although not all forward-looking statements contain such identifying words. In making these statements, we rely upon assumptions and analysis based on our experience and perception of historical trends, current conditions, and expected future developments, as well as other factors we consider appropriate under the circumstances. We believe these judgments are reasonable, but these statements are not guarantees of any future events or financial results. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond our control.

These forward-looking statements are subject to a number of risks and uncertainties, including changes in domestic and foreign business, market, financial, political and legal conditions; failure to realize the anticipated benefits of the business combination; risks relating to the uncertainty of our projected financial information; future global, regional or local economic and market conditions; the development, effects and enforcement of laws and regulations; our ability to manage future growth; our ability to develop new products and services, bring them to market in a timely manner and make enhancements to our platform; the effects of competition on our future business; our ability to issue equity or equity-linked securities; the outcome of any potential litigation, government and regulatory proceedings, investigations and inquiries; and those factors described or referenced in filings with the Securities and Exchange Commission. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that we do not presently know or that we currently believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect our expectations, plans or forecasts of future events and views as of the date of this press release. We anticipate that subsequent events and developments will cause our assessments to change.

We caution readers not to place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date they are made, and we undertake no obligation to update publicly or otherwise revise any forward-looking statements, whether as a result of new information, future events, or other factors that affect the subject of these statements, except where we are expressly required to do so by law. All written and oral forward-looking statements attributable to us are expressly qualified in their entirety by this cautionary statement.

Contacts:

Investors 
Cody Slach
Gateway Group, Inc. 
949-574-3860 
BTM@gateway-grp.com

Media 
Brenlyn Motlagh, Ryan Deloney 
Gateway Group, Inc.
949-574-3860 
BTM@gateway-grp.com

Source: Bitcoin Depot Inc.

Released February 3, 2025

Trump’s Trade Tsunami: Stocks Plummet as Tariffs Hit Global Markets

Posted on February 3, 2025February 3, 2025 by slightbourne@noblecapitalmarkets.com

Key Points:
– Trump implements 25% tariffs on Canada and Mexico, 10% on China
– Retaliatory measures from trading partners already in motion
– Multiple industries expected to face significant price increases

Wall Street experienced a seismic shock as President Trump’s aggressive tariff strategy sent financial markets into a tailspin, with major indexes suffering significant losses and investors bracing for potential economic repercussions. The Nasdaq Composite plummeted over 2%, while the S&P 500 spiraled 1.6% and the Dow Jones Industrial Average tumbled more than 550 points.

The sweeping tariffs, set to take effect on Tuesday, include 25% duties on Canada and Mexico, and 10% on China, with energy imports from Canada receiving a slightly lower 10% rate. Trump’s announcement has sent shockwaves through global markets, with the president already hinting at potential future tariffs on the European Union.

Goldman Sachs strategists warn that these tariffs could potentially reduce S&P 500 earnings forecasts by 2-3%, with a potential market value decline of approximately 5%. The move has caught many investors off guard, who had previously expected tariffs would only be imposed after failed trade negotiations.

The tariffs’ impact extended dramatically into the energy sector, with oil prices experiencing significant volatility. West Texas Intermediate crude futures jumped as much as 3.7%, outpacing global benchmarks and highlighting potential supply chain disruptions. The 10% levy on Canadian energy imports and 25% tariff on Mexican crude supplies threaten to reshape North American energy dynamics.

Refineries in the Midwest, which heavily rely on Canadian heavy crude, are particularly vulnerable. The tariffs are expected to cause immediate price increases, with refiners like Irving Oil already signaling potential fuel price hikes. The strategic oil storage hub in Cushing, Oklahoma, and Gulf Coast refineries will feel the most immediate effects of these trade barriers.

Commodities experts warn that while the tariffs might provide a short-term boost to oil prices, they raise substantial concerns about global economic growth. The complex energy supply chain could face significant restructuring, potentially increasing fuel costs for American consumers and challenging the intricate economic relationships between the United States, Canada, and Mexico.

Retaliatory measures were swift, with Canadian Prime Minister Justin Trudeau announcing 25% counter-tariffs on approximately $107 billion of American-made products. The tit-for-tat escalation threatens to create a complex web of economic challenges for multiple nations.

Consumer discretionary stocks bore the brunt of the market reaction, with automakers and tech companies experiencing significant downturns. Tech giants like Nvidia and Apple saw substantial share price declines, reflecting broader market anxieties about the potential long-term economic implications of these tariffs.

The Federal Reserve remains cautious, with interest rates held steady due to concerns about potential inflationary pressures. The tariffs are expected to directly impact consumers across multiple industries, with potential price increases anticipated for automobiles, auto parts, clothing, computers, and various other goods.

Noble Capital Markets’ Research Analyst Joe Gomes suggests that while the full implications of these tariffs remain uncertain, companies have been proactively preparing for potential trade barriers. Over the past few months, many businesses have been developing contingency strategies to mitigate the immediate economic impact, implementing supply chain adjustments and financial buffers to minimize potential disruptions from the new tariff regime.

The global economic landscape now appears increasingly uncertain, with trade tensions threatening to disrupt carefully established international economic relationships. Technology and manufacturing sectors seem particularly vulnerable to these protectionist measures.

Release – GeoVax Announces Strategic Integration of AI in Support of President Trump’s Stargate Initiative

Posted on February 3, 2025February 3, 2025 by aweinsoff@channelchek.com

Research News and Market Data on GOVX

Harnessing AI to Revolutionize Vaccine and Therapy Development

ATLANTA, GA, February 3, 2025 — GeoVax Labs, Inc. (Nasdaq: GOVX), a leader in vaccine and immunotherapy development, announced today its endorsement of President Donald J. Trump’s Stargate Initiative, which aims to harness advanced technologies including Artificial Intelligence (AI) to strengthen U.S. healthcare, biosecurity, and global innovation leadership. This announcement aligns with GeoVax’s commitment to leveraging AI across its vaccine and cancer immunotherapy programs to accelerate research, optimize operations, and deliver life-saving solutions.

Revolutionizing Healthcare with AI

GeoVax has embedded AI into its platforms for vaccine development and cancer immunotherapy, enabling groundbreaking advances:

Vaccine Development: AI drives target discovery and design for vaccines using the Modified Vaccinia Ankara (MVA) platform, including GEO-CM04S1, GeoVax’s next-generation vaccine for COVID-19, and vaccines for Mpox and Smallpox. AI predicts pathogen mutations, ensuring long-lasting and variant-proof vaccines.
Cancer Immunotherapy: AI optimizes GeoVax’s Gene-Directed Enzyme Prodrug Therapy (GDEPT) for solid tumors, including predictive modeling of tumor microenvironments, real-time adjustment of protocols to maximize therapeutic efficacy, and identifying synergistic combinations with immune checkpoint inhibitors.
Clinical Targeting: AI-powered analytics will refine patient stratification, ensuring that GeoVax’s therapies reach underserved populations most in need, aligning with the initiative’s national focus to maximize therapeutic efficacy.
Manufacturing and Operations: AI improves GeoVax’s vaccine production scalability and supply chain management, ensuring timely delivery to strategic stockpiles.

Aligned with the Stargate Vision

President Trump’s Stargate Initiative, supported by up to $500 billion in private-sector investment, represents a bold step forward in embracing transformative technologies. GeoVax proudly aligns with this vision, advancing U.S. healthcare innovation and pandemic preparedness.

David Dodd, GeoVax Chairman and CEO, stated: “President Trump’s Stargate Initiative exemplifies leadership in harnessing AI to address critical healthcare challenges. GeoVax is honored to support this initiative, highlighting its application of AI to develop vaccines and therapies that save lives and enhance biosecurity. We are proud to contribute to a future where the United States leads the world in healthcare innovation.”

Building on Operation Warp Speed’s Legacy

GeoVax’s efforts reflect the spirit of President Trump’s Operation Warp Speed, which accelerated COVID-19 vaccine development and deployment. By integrating AI into its research and operational strategies, GeoVax aims to continue pushing the boundaries of what is possible in medical science.

A Commitment to Life-Saving Innovation

GeoVax remains steadfast in its mission to develop innovative vaccines and immunotherapies, leveraging the power of AI to meet the healthcare needs of today and prepare for the challenges of tomorrow. With AI now embedded in its processes, GeoVax anticipates shorter development timelines, increased efficiency in clinical trials, and enhanced capacity to deliver life-saving therapies globally. Collaborations with academic institutions, industry partners and federal agencies will further amplify the reach and impact of GeoVax’s innovative programs under the Stargate framework. AI-enabled supply chain optimization will further ensure efficient vaccine distribution to high-priority populations and regions.

About GeoVax

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines for many of the world’s most threatening infectious diseases and therapies for solid tumor cancers. The company’s lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine for which GeoVax was recently awarded a BARDA-funded contract to sponsor a 10,000-participant Phase 2b clinical trial to evaluate the efficacy of GEO-CM04S1 versus an approved COVID-19 vaccine. In addition, GEO-CM04S1 is currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. A Phase 2 clinical trial in first recurrent head and neck cancer, evaluating Gedeptin^® combined with an immune checkpoint inhibitor is planned to initiate in mid-2025. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. The Company has a leadership team who have driven significant value creation across multiple life science companies over the past several decades. For more information about the current status of our clinical trials and other updates, visit our website: www.geovax.com.

Forward-Looking Statements

This release contains forward-looking statements regarding GeoVax’s business plans. The words “believe,” “look forward to,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax is able to obtain acceptable results from ongoing or future clinical trials of its investigational products, GeoVax’s immuno-oncology products and preventative vaccines can provoke the desired responses, and those products or vaccines can be used effectively, GeoVax’s viral vector technology adequately amplifies immune responses to cancer antigens, GeoVax can develop and manufacture its immuno-oncology products and preventative vaccines with the desired characteristics in a timely manner, GeoVax’s immuno-oncology products and preventative vaccines will be safe for human use, GeoVax’s vaccines will effectively prevent targeted infections in humans, GeoVax’s immuno-oncology products and preventative vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete development, there is development of competitive products that may be more effective or easier to use than GeoVax’s products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control.

Further information on our risk factors is contained in our periodic reports on Form 10-Q and Form 10-K that we have filed and will file with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

Company Contact:	Investor Relations Contact:	Media Contact:
info@geovax.com	austin.murtagh@precisionaq.com	sr@roberts-communications.com
678-384-7220	212-698-8696	202-779-0929